An interventional study of High-dose home-tDCS M1 and Conventional home-tDCS in Fibromyalgia (FM), sponsored by Ionclinics & Deionic SL. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Ionclinics & Deionic SL · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Fibromyalgia with a site in Spain — 16 open to participants now, 21 under way, none of them phase 3. Fibromyalgia · Spain.
Among the 151 studies in Fibromyalgia with a site in Spain, this one is the 15th largest by planned enrollment of the 135 interventional ones that give a count, is one of 6 that started in 2026, is one of 113 with no phase, reaches primary completion later than 20 of the 20 other live ones, and was the 147th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →16 of the 151 studies in Fibromyalgia with a site in Spain are open now. Recruiting first, the newest first:
European University Miguel de Cervantes · Sites in Spain
Ages 18+ · Women only
University of Valladolid · Sites in Spain
Ages 18+
Cardenal Herrera University · Sites in Spain
Ages 18–80
Parc de Salut Mar · Sites in Spain
Ages 18–70 · Women only
Universitat de Lleida · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 66 across the 135 interventional studies, 90 across the 15 observational. Of the 107 that completed or were terminated, 10 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 151 have an industry lead sponsor. The 10 most frequent:
Ionclinics & Deionic SL is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Ionclinics & Deionic SL has 1 study filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Fibromyalgia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424534University of Castilla-La ManchaPredictive Models on Psychosocial Profile, Fatigue and Sleep Quality | 2026-11-30 |
| NCT06948500Cardenal Herrera UniversityEffectiveness of an IVR-based Therapeutic Exercise Program With Altered Visual Feedback in Fibromyalgia Patients | 2026-12-01 |
| NCT07693998University of ValenciaPain Neuroscience Education for Chronic Pain | 2026-12-31 |
| NCT04084795Parc de Salut MarAugmentation of EMDR With tDCS in the Treatment of Fibromyalgia | 2026-12-31 |
| NCT05962437Fundació Sant Joan de DéuSelf-guided Acceptance and Commitment Therapy-based Digital Smartphone Application for Management of Fibromyalgia | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 151 studies in Fibromyalgia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its cost-effectiveness, in patients with fibromyalgia.
As complementary goals, we aim to assess the predictive value of baseline EEG for clinical response to high-dose home-based tDCS treatment; and to describe the effectiveness of a high-dose home-based protocol applied to the motor cortex (M1) versus the dorsolateral prefrontal cortex (DLFPC) in patients with fibromyalgia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tDCS administered at home using a high-dose protocol targeting the primary motor cortex.
Device: High-dose home-tDCS M1
tDCS administered at home using a conventional stimulation protocol targeting the primary motor cortex.
Device: Conventional home-tDCS
tDCS administered at home using a high-dose stimulation protocol targeting the dorsolateral prefrontal cortex.
Device: High-dose home-tDCS DLPFC
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique in which a weak direct current (2 mA) is applied to the scalp via electrodes. The anode will be applied to C3 (primary motor cortex) and the cathode to Fp2 (contralateral anterior frontal region). The application of tDCS will be carried out at home in this group. Each session will consist of 20 minutes of stimulation. Dose: 3 weeks, daily. (1) 1st week - 3 times per day; (2) 2nd Week - 2 times per day; (3) 3rd week - 1 time per day (total of 42 sessions).
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique in which a weak direct current (2 mA) is applied to the scalp via electrodes. The anode will be applied to C3 (primary motor cortex) and the cathode to Fp2 (contralateral anterior frontal region). The application of tDCS will be carried out at home in this group. Each session will consist of 20 minutes of stimulation. Dose: 4 weeks, from Monday to Friday. 1 time per day (total of 20 sessions).
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique in which a weak direct current (2 mA) is applied to the scalp via electrodes. The anode will be applied to F3 (left dorsolateral prefrontal cortex) and the cathode to F8 (right ventrolateral prefrontal cortex). The application of tDCS will be carried out at home in this group. Each session will consist of 20 minutes of stimulation. Dose: 3 weeks, daily. (1) 1st week - 3 times per day; (2) 2nd Week - 2 times per day; (3) 3rd week - 1 time per day (total of 42 sessions).
Fibromyalgia Impact Questionnaire
Changes from baseline to the end of the treatment in the revised version of Fibromyalgia Impact Questionnaire (FIQ-R).
Time frame: Baseline and end of treatment (week 3 for experimental; week 4 for active comparator).
WPI
Change from baseline to end of treatment in Widespread Pain Inventory (WPI).
Time frame: Baseline; end of treatment (3 week experimental; 4 week active comparator)
SSS
Change from baseline to end of treatment in Symptom Severity Scale (SSS).
Time frame: Baseline; end of treatment (3 week experimental; 4 week active comparator)
HADS
Change from baseline to end of treatment in Hospital Anxiety and Depression Scale (HADS).
Time frame: Baseline; end of treatment (3 week experimental; 4 week active comparator).
PSQI
Change from baseline to end of treatment in Pittsburgh Sleep Quality Index (PSQI).
Time frame: Baseline; end of treatment (3 week experimental; 4 week active comparator).
EQ-5D
Change from baseline to end of treatment in EuroQoL-5D (EQ-5D).
Time frame: Baseline; end of treatment (3 week experimental; 4 week active comparator).
PGI-C
Change at the end of treatment in Patient Global Impression of Change (PGI-C).
Time frame: End of treatment (3 week experimental; 4 week active comparator).
BDI-II
Changes from baseline to end of treatment in Beck Depression Inventory-II.
Time frame: Baseline and end of treatment (week 3 for experimental; week 4 for active comparator).
Resting state EEG
32-channel active-electrode EEG (impedances \<5 kΩ) recordings in open and close eye conditions. The spectral density and spectral power of delta, theta, alpha, beta, and gamma will be analyzed, as well as the topographic distribution.
Time frame: Baseline
Responders to tDCS
A subject is considered a responder if: \- Improvement of 50% or more in FIQ-R from baseline to immediate post-treatment.
Time frame: Through study completion, an average of 2 years.
Adverse Effect
A daily questionnaire about adverse effects will be completed at the end of the last intervention of the day.
Time frame: End-of-day application (Experimental: 7 days per week through 3 weeks; Active Comparator: 5 days per week, through 4 weeks).
Success of blinding
A method 3 x 3 will be used to evaluate the success of the study's evaluator and statistician.
Time frame: Through study completion, an average of 2 years
Patient Expectations
Likert scale from 1 to 5 (where 1 is no expectation and 5 is the highest possible expectation) to study the influence of expectation on the effect of treatment.
Time frame: Baseline
Incremental Cost Effectiveness Ratio
Incremental Cost Effectiveness Ratio (ICER) will be derived from clinical effectiveness, utility and costs.
Time frame: Through study completion, an average of 2 years.
Costs
Direct and indirect medical and non-medical costs will be collected for the cost-effectiveness analysis.
Time frame: Through study completion, an average of 2 years.
Utility
Quality-adjusted life years (QALYs) will be calculated using the EQ-5D questionnaire for the cost-effectiveness analysis.
Time frame: Through study completion, an average of 2 years.
NRS
Daily report of the numeric rating scale for symptom intensity, ranging from 0 to 10 (with 0 meaning 'none' and 10 meaning 'the worst imaginable').
Time frame: Each day during the treatment (21 days for experimental; 28 days for active comparator).
Plan to share: No — In accordance with the recommendations of the International Committee of Medical Journal Editors, the de-identified individual participant data (IPD) that underlie the results reported in this study will be shared. The data will become accessible one year after the publication of the primary results and will remain available for five years. Access will be provided to researchers who inquire and agree to a data-use agreement through Ionclinics (investigacion@ionclinics.com/ensayos@ionclinics.com). The data will be de-identified and shared in accordance with applicable regulations and the informed consent provided by the participants.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.
Of 451 interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 17 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ionclinics & Deionic SL